PriceTargets.com logo

NASDAQ:NTEC - Intec Pharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $52.00
  • Forecasted Upside: ∞
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 12/31/1969 06:45 PM ET
+0.30 (1.20%)
Get New Intec Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NTEC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NTEC

Analyst Price Target is $52.00
▲ +∞ Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Intec Pharma in the last 3 months. The average price target is $52.00, with a high forecast of $52.00 and a low forecast of $52.00. The average price target represents a ∞ upside from the last price of $0.00.

This chart shows the closing price for NTEC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Intec Pharma. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
4/28/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/27/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/25/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
1/23/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
4/23/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
7/22/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/20/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/15/2020Roth CapitalReiterated RatingNeutralLow
12/9/2020LADENBURG THALM/SH SHUpgradeNeutral ➝ Buy$52.00High
10/9/2020HC WainwrightReiterated RatingHoldLow
8/17/2020HC WainwrightReiterated RatingNeutralHigh
8/6/2020Maxim GroupReiterated RatingHoldMedium
5/18/2020LADENBURG THALM/SH SHReiterated RatingHoldHigh
4/13/2020HC WainwrightReiterated RatingHoldHigh
12/12/2019HC WainwrightReiterated RatingHoldMedium
12/2/2019HC WainwrightReiterated RatingHoldHigh
10/11/2019Roth CapitalDowngradeBuy ➝ Neutral$800.00 ➝ $80.00Low
8/12/2019LADENBURG THALM/SH SHReiterated RatingHoldHigh
8/7/2019HC WainwrightDowngradeBuy ➝ NeutralMedium
7/22/2019OppenheimerDowngradeOutperform ➝ Market PerformHigh
7/22/2019LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralHigh
7/22/2019Maxim GroupDowngradeBuy ➝ HoldN/A
6/20/2019HC WainwrightSet Price TargetBuy$1,280.00High
6/20/2019Maxim GroupReiterated RatingBuy$960.00High
6/20/2019LADENBURG THALM/SH SHReiterated RatingBuy$1,200.00Low
5/28/2019HC WainwrightSet Price TargetBuy$1,280.00Medium
5/16/2019LADENBURG THALM/SH SHReiterated RatingBuyHigh
5/1/2019LADENBURG THALM/SH SHReiterated RatingBuyLow
2/28/2019LADENBURG THALM/SH SHReiterated RatingBuy$1,200.00Low
2/22/2019OppenheimerSet Price TargetBuy$1,200.00Medium
2/19/2019Maxim GroupReiterated RatingBuy$960.00High
1/29/2019LADENBURG THALM/SH SHReiterated RatingBuy$960.00N/A
1/4/2019HC WainwrightReiterated RatingBuy$1,280.00Medium
12/10/2018HC WainwrightReiterated RatingBuy$1,280.00High
12/2/2018OppenheimerSet Price TargetBuy$1,200.00High
11/15/2018OppenheimerSet Price TargetBuy$1,200.00Medium
10/24/2018HC WainwrightSet Price TargetBuy$1,280.00Medium
10/5/2018Roth CapitalInitiated CoverageBuy$680.00High
9/30/2018OppenheimerSet Price TargetBuy$1,200.00Medium
8/16/2018HC WainwrightSet Price TargetBuy$1,280.00Medium
8/15/2018OppenheimerSet Price TargetBuy$1,200.00Medium
6/26/2018Roth CapitalReiterated RatingBuy$800.00Low
5/24/2018OppenheimerSet Price TargetBuy$1,200.00High
5/22/2018HC WainwrightSet Price TargetBuy$1,280.00Medium
5/7/2018HC WainwrightSet Price TargetBuy$1,280.00Low
4/11/2018OppenheimerSet Price TargetBuy$1,200.00Low
3/26/2018Maxim GroupBoost Price TargetBuy ➝ Buy$640.00 ➝ $960.00Medium
3/21/2018OppenheimerReiterated RatingBuyLow
3/18/2018HC WainwrightSet Price TargetBuy$1,280.00Low
3/13/2018OppenheimerSet Price TargetBuy$1,200.00Low
3/12/2018HC WainwrightReiterated RatingBuy$1,280.00Medium
3/7/2018OppenheimerSet Price TargetBuy$1,200.00Low
2/28/2018LADENBURG THALM/SH SHInitiated CoverageBuy ➝ BuyMedium
2/26/2018HC WainwrightInitiated CoverageBuy ➝ BuyHigh
12/18/2017OppenheimerSet Price TargetBuy$1,200.00Low
11/17/2017Maxim GroupSet Price TargetBuy$720.00 ➝ $640.00N/A
11/16/2017OppenheimerSet Price TargetBuy$1,200.00N/A
10/13/2017OppenheimerSet Price TargetBuy$1,200.00N/A
9/21/2017CIBCReiterated RatingOutperform ➝ Outperform$800.00 ➝ $1,200.00Medium
9/21/2017OppenheimerBoost Price TargetOutperform$800.00 ➝ $1,200.00High
8/10/2017Roth CapitalSet Price TargetBuy$800.00High
8/3/2017Roth CapitalSet Price TargetBuy$800.00Low
5/24/2017Maxim GroupSet Price TargetBuy$720.00Low
3/24/2017Maxim GroupReiterated RatingBuy$720.00Low
(Data available from 10/20/2016 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/24/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/22/2021
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/20/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/20/2021

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Intec Pharma logo
Intec Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of drugs based on proprietary Accordion Pill platform technology. Its Accordion Pill technology is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs under development by utilizing an efficient gastric retention and specific release mechanism. The company was founded by Zvika Joseph on October 23, 2000 and is headquartered in Jerusalem, Israel.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $13.52
Low: $9.15
High: $36.20

52 Week Range

Now: N/A

Volume

988,300 shs

Average Volume

543,436 shs

Market Capitalization

$8.65 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83

Frequently Asked Questions

What sell-side analysts currently cover shares of Intec Pharma?

The following Wall Street research analysts have issued stock ratings on Intec Pharma in the last year: LADENBURG THALM/SH SH, Roth Capital, and Zacks Investment Research.
View the latest analyst ratings for NTEC.

What is the current price target for Intec Pharma?

1 Wall Street analysts have set twelve-month price targets for Intec Pharma in the last year. Their average twelve-month price target is $52.00. LADENBURG THALM/SH SH has the highest price target set, predicting NTEC will reach $52.00 in the next twelve months. LADENBURG THALM/SH SH has the lowest price target set, forecasting a price of $52.00 for Intec Pharma in the next year.
View the latest price targets for NTEC.

What is the current consensus analyst rating for Intec Pharma?

Intec Pharma currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NTEC will outperform the market and that investors should add to their positions of Intec Pharma.
View the latest ratings for NTEC.

How do I contact Intec Pharma's investor relations team?

Intec Pharma's physical mailing address is 12 HARTOM STREET HAR HOTZVIM, JERUSALEM L3, 777512. The biotechnology company's listed phone number is (722) 586-4657 and its investor relations email address is [email protected] The official website for Intec Pharma is www.intecpharma.com.